Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: INCRELEX

« Back to Dashboard

Summary for Tradename: INCRELEX

Patents:3
Applicants:1
NDAs:1
Suppliers: see list1

Clinical Trials for: INCRELEX

IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex
Status: Active, not recruiting Condition: Primary Insulin-like Growth Factor-1 Deficiency

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
Status: Completed Condition: Insulin-like Growth Factor-1 Deficiency

Effect of Increlex® on Children With Crohn Disease
Status: Recruiting Condition: Crohn Disease

Long-Term Treatment With rhIGF-1 in GHIS
Status: Active, not recruiting Condition: Growth Hormone Insensitivity Syndrome

European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry
Status: Recruiting Condition: IGF1 Deficiency

Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)
Status: Completed Condition: Rett Syndrome

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
Status: Completed Condition: Insulin-Like Growth Factor-1 Deficiency; Growth Disorders

Treatment of Rett Syndrome With Recombinant Human IGF-1
Status: Recruiting Condition: Rett Syndrome

Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa
Status: Completed Condition: Disorder of Bone Density and Structure, Unspecified

Increlex Treatment of Children With Chronic Liver Disease and Short Stature
Status: Not yet recruiting Condition: Growth Failure; Chronic Liver Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Inc
INCRELEX
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839Aug 30, 2005RXYes5,824,642<disabled><disabled>
Ipsen Inc
INCRELEX
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839Aug 30, 2005RXYes5,681,814<disabled>Y<disabled>
Ipsen Inc
INCRELEX
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839Aug 30, 2005RXYes6,207,640<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc